Boots
This article was originally published in The Rose Sheet
Executive Summary
Beauty and toiletries sales advanced 4.7% to $3.7 bil. (£1=$1.84), with premium cosmetics growing 10%, boosted by a strong seasonal gift program and expanded distribution, British retailer says in preliminary FY 2003 (ended March 31) results. Fragrance sales were up on new launches, Boots adds. In addition, sunshop sales increased 17%. Toiletries volume was modest, due in part to price reductions in the category, firm notes. Boots The Chemist generated sales of $8.26 bil., up 4.5% adjusted for currency, or 3.9% like-for-like. Operating profit declined 6.6% to $975 mil. Sales in Boots Healthcare International improved 9.6%, or 7.8% in local currency, to $619.7 mil. Clearasil sales were up 6% overall, but dropped 3% in the U.S. "due to substantial pipeline fill in 2002/2003," according to the retailer. Operating profit grew 15% to $148 mil. Group sales improved 5% to $9.8 bil., with group operating profit from continuing operations up 6% to $1 bil...
You may also be interested in...
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.
‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports
The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.